West Pharmaceutical Services (WST) Q4 2025 Earnings
How Did WST Stock React to Q4 2025 Earnings?
S&P 500 over the same 30 days: −1.54%.
Did WST Beat Earnings? Q4 2025 Results
Yes. West Pharmaceutical Services reported Q4 2025 earnings of $2.04 a share on Feb 12, 2026, beating the $1.83 consensus estimate by 11.5%. Revenue was $805.0M against a $794.8M estimate.
West Pharmaceutical Services closed out fiscal 2025 on a strong note, posting Q4 adjusted diluted EPS of $2.04, beating the $1.83 consensus estimate by 11.48%, as revenue climbed 7.5% year-over-year to $805.00 million. The standout driver was a 15.1% organic surge in High-Value Product Components, fueled by demand for Westar and Envision products, while GLP-1-related revenues proved a meaningful contributor, with elastomers alone accounting for 10% of total company sales in the quarter. Gross margin expanded 130 basis points to 37.8%, and adjusted diluted EPS grew 12.1% versus the prior-year period. For the full year, free cash flow jumped 69.6% to $468.90 million, a performance strong enough to support a newly authorized $1 billion share repurchase program alongside a quarterly dividend of $0.22 per share. Looking ahead, management guided fiscal 2026 net sales of $3.21 billion to $3.27 billion and adjusted EPS of $7.85 to $8.20, representing earnings growth of 7.7% to 12.5%, with Contract Manufacturing margins expected to recover to historical levels as early as Q1 2026.
- Double-digit organic growth in HVP Components driven by Westar and Envision products
- GLP-1 elastomers represented 10% of total company revenues in Q4
- GLP-1 Contract Manufacturing revenues represented 7% of total company revenues in Q4
- Biologics market group accounted for 42% of Q4 revenue
- Favorable foreign currency translation contributed 4.2 percentage points to Q4 revenue growth
- EMEA region led geographic growth at 14.6% year-over-year
“Our strong finish to 2025 was a result of the team's relentless execution of our growth strategy. Our performance in the quarter was led by our High-Value Product Components business in our Proprietary Products Segment, enabling us to deliver double-digit adjusted earnings per share growth. We expect positive momentum to continue in 2026, which will be a key year of execution and operational excellence to drive sustainable growth and create value for our patients, customers and shareholders.”
West Pharmaceutical Services CEO, on the earnings call
What Was West Pharmaceutical Services's Outlook in Q4 2025?
For fiscal 2026, West expects net sales of $3.215 billion to $3.275 billion, representing reported growth of 4.6% to 6.5% and organic growth of approximately 5% to 7%. Full-year 2026 adjusted diluted EPS is expected to be $7.85 to $8.20, representing growth of 7.7% to 12.5%. Guidance assumes a mid-year 2026 close for the SmartDose 3.5mL sale to AbbVie and includes an estimated 2 percentage point full-year benefit from current foreign currency exchange rates. Capital expenditures are expected to be $250 million to $275 million. For Q1 2026, net sales are expected to be $770 million to $790 million with adjusted diluted EPS of $1.65 to $1.70. Contract Manufacturing operating margins are expected to return to historical levels in Q1 2026 following remediation of a temporary Arizona facility disruption.
WST YoY Financials
| Metric | Q4 2025 | Q4 2024 | Year over year |
|---|---|---|---|
| Revenue | $805.0M | $748.5M | +7.5% |
| Gross Profit | $303.9M | $274.4M | +10.8% |
| Operating Income | $156.6M | $170.6M | −8.2% |
| Net Income | $132.1M | $130.1M | +1.5% |
WST Revenue by Segment
WST Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.